Composition for preventing or treating cancer pain

A serotonin 3 receptor agonist-based composition effectively treats cancer pain with reduced side effects, matching morphine's efficacy in pain threshold increase while minimizing central nervous system impact.

WO2024242158A1PCT designated stage expired Publication Date: 2024-11-28MARUISHI PHARMACEUTICAL CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018940
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for cancer pain, particularly those involving opioids and non-opioid analgesics like pregabalin, often come with significant side effects such as dependence, tolerance, somnolence, and reduced central nervous system function, and are not effective for all cancer pain models.

Method used

A pharmaceutical composition containing a compound represented by the general formula (I) or its pharmaceutically acceptable salt, which acts as a serotonin 3 receptor agonist, is developed to provide effective prevention and treatment of cancer pain without the aforementioned side effects, comparable to morphine in efficacy.

Benefits of technology

The composition significantly increases the cancer pain threshold, offering effective analgesia comparable to morphine with minimal side effects on the central nervous system, such as sedation or locomotor activity suppression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018940_28112024_PF_FP_ABST
    Figure JP2024018940_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to provide a prophylactic or therapeutic agent for cancer pain. The present invention provides a pharmaceutical composition for preventing or treating cancer pain, the composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. [In the formula, m is an integer of 1-4; and R1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1-3 halogen atoms, a methoxy group optionally substituted with 1-3 halogen atoms, and a methylthio group optionally substituted with 1-3 halogen atoms.]
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing or treating cancer pain

[0001] The present invention relates to a composition for preventing or treating cancer pain.

[0002] Cancer is one of the three leading causes of death in Japan. Cancer symptoms vary depending on the type and location of the cancer, but a typical symptom is cancer pain. It is said that cancer pain is present in 70-80% of all patients with advanced cancer.

[0003] It is believed that relief from cancer pain is essential for improving the quality of life (QOL) of cancer patients (Non-Patent Document 1).

[0004] In drug therapy for cancer pain, analgesics are selected in the order of the WHO three-step analgesic ladder, with analgesics selected according to the level of pain. As the levels increase to the second and third steps, opioids become the primary focus of drug treatment. However, opioids are known to cause various side effects, including dependence (psychological dependence, physical dependence), tolerance (analgesic tolerance), and somnolence.

[0005] It has been reported that many drugs, except for opioids, are ineffective against cancer pain after a single dose in animal models of cancer pain (Non-Patent Documents 2 to 7). Pregabalin, a non-opioid analgesic, has been reported to be effective in animal models of cancer pain, but is known to have sedative effects such as dizziness, somnolence, and loss of consciousness as side effects (Non-Patent Documents 2 and 8). Non-Patent Document 9 describes the evaluation of pregabalin's effects on the central nervous system by assessing coordination and spontaneous motor activity in rats using the rotarod method and the Supermex method, and it is known that pregabalin suppresses central nervous function (inhibits coordination) at doses lower than those that exhibit an analgesic effect (Table 2 in Non-Patent Document 9).

[0006] Under these circumstances, there is a need for the development of effective therapeutic drugs for cancer pain.

[0007] On the other hand, 1-(6-chloropyridin-2-yl)piperidin-4-amine (hereinafter also referred to as "Compound A") is known to be a serotonin 3 receptor agonist (Patent Documents 1 and 2). Patent Document 3 discloses a pharmaceutical composition for preventing or treating chronic pain, comprising a serotonin 3 receptor agonist, including Compound A, and a pharmaceutically acceptable carrier. Here, chronic pain is defined as "pain that persists beyond the time expected to be required for healing, or pain associated with a progressive non-cancer disease" (Non-Patent Document 1). It is not known that this composition is effective against cancer pain. Furthermore, it has been reported that SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-noradrenaline reuptake inhibitors), which share the same serotonin-mediated involvement as this serotonin 3 receptor agonist, are ineffective against cancer pain in animal models of cancer pain (Non-Patent Documents 2 and 3).

[0008] Guidance for the Appropriate Use of Medical Narcotics, Ministry of Health, Labor and Welfare, Pharmaceutical and Food Safety Bureau, Surveillance and Narcotics Control Division, April 2017. Mohammad Zafar Imam et al., Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain, Pharmacological Reports, July 26, 2020, Vol. 72, pp. 1418-1425. Mohammed El Mouedden et al., Pharmacological evaluation of opioid and non-opioid analgesis in a murine bone cancer model of pain, Pharmacology, Biochemistry and Behavior, January 12, 2007, Vol. 86, pp. 458-467. Janette Nallely Corona-Ramos et al., The effect of gabapentin and tramadol in cancer pain induced by glioma cells in rat feces, Drug Development Research, 2017, Vol. 78, pp. 173-183 Simeng Ma et al., Amitriptyline influences the mechanical withdrawal threshold in bone cancer pain rats by regulating glutamate transporter GLAST, Molecular Pain, 2019, Vol. 15, pp. 1-12 Tansy Donovan-Rodriguez et al.Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-Induced Bone Pain, Anesthesiology, 2005, Vol. 102, pp. 132-140; Osamu Saito et al., Analgesic Effects of Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and Morphine in a Mouse Model of Bone Cancer Pain, Journal of Anesthesia, 2005, Vol. 19, pp. 218-224; Viatris Pharmaceutical Co., Ltd., Lyrica (registered trademark) Capsules and OD Tablets 25 mg, 75 mg, and 150 mg Package Inserts, Revised July 2022 (3rd Edition); Kitano Yutaka et al., Japanese Journal of Pharmacology, 2019, Vol. 154, pp. 352-361,

[0009] JP-A-56-36481 JP-A-7-145166 Patent No. 7090344

[0010] An object of the present invention is to provide a drug for preventing or treating cancer pain.

[0011] As a result of extensive research to solve the above problems, the present inventors have found that a compound represented by the following general formula (I) has excellent effects in preventing or treating cancer pain, and have thus completed the present invention.

[0012] That is, the present invention relates to the following compositions: [1] A pharmaceutical composition for preventing or treating cancer pain, comprising a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier: wherein m is an integer of 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1 to 3 halogen atoms, a methoxy group optionally substituted with 1 to 3 halogen atoms, and a methylthio group optionally substituted with 1 to 3 halogen atoms. 1[3] The pharmaceutical composition according to the above-mentioned [1], wherein each R is independently a halogen atom. 1 [4] The pharmaceutical composition according to any one of the above [1] to [3], wherein m is 1. [5] The compound represented by formula (I) or a pharmaceutically acceptable salt thereof is represented by the following formula (I'): [In the formula, R 1 [6] The pharmaceutical composition according to any one of the above [1] to [4], wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is a compound represented by the following formula: [7] A pharmaceutical composition according to any one of the above [1] to [5], which is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [8] A pharmaceutical composition according to any one of the above [1] to [5], which is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, 1 has the same meaning as any one of the above [1] to [4]. [8] A cancer pain threshold elevating agent comprising the compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof (provided that m and R 1 has the same meaning as any one of the above [1] to [4]. [9] The agent according to the above [7] or [8], wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is compound A or a pharmaceutically acceptable salt thereof.

[10] A method for preventing or treating cancer pain, comprising administering an effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof to a human or a non-human animal (provided that m and R in formula (I) 1 has the same meaning as any one of the above [1] to [4].

[11] A method for increasing the threshold of cancer pain, which comprises administering to a human or a non-human animal an effective amount of a compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof (provided that m and R in formula (I) 1has the same meaning as any one of the above [1] to [4].

[12] The method according to the above

[10] or

[11] , wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is compound A or a pharmaceutically acceptable salt thereof.

[13] Use of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the prevention or treatment of cancer pain or an agent for the prevention or treatment of cancer pain (provided that m and R 1 has the same meaning as any one of the above [1] to [4].

[14] Use of the compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition or an agent for increasing the cancer pain threshold (provided that m and R 1 has the same meaning as any one of the above [1] to [4].

[15] The use according to the above

[13] or

[14] , wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is compound A or a pharmaceutically acceptable salt thereof.

[16] Use of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof for the prevention or treatment of cancer pain (provided that m and R 1 has the same meaning as any one of the above [1] to [4].

[17] Use of the compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof for increasing the threshold of cancer pain (provided that m and R 1 has the same meaning as any one of the above [1] to [4].

[18] The use according to the above

[16] or

[17] , wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is compound A or a pharmaceutically acceptable salt thereof.

[19] The compound represented by formula (I) or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of cancer pain (provided that m and R 1 has the same meaning as any one of the above [1] to [4].

[20] A compound represented by the above formula (I) or a pharmaceutically acceptable salt thereof for use in increasing cancer pain threshold (provided that m and R 1has the same meaning as any one of the above [1] to [4].

[21] The compound or a pharmaceutically acceptable salt thereof for use according to the above

[19] or

[20] , wherein the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is compound A or a pharmaceutically acceptable salt thereof.

[22] The pharmaceutical composition according to any one of the above [1] to [6], the agent according to any one of the above [7] to [9], the method according to any one of the above

[10] to

[12] , the use according to any one of the above

[13] to

[18] , or the compound or a pharmaceutically acceptable salt thereof for use according to any one of the above

[19] to

[21] , wherein the cancer pain is at least one selected from pain directly caused by the cancer itself, pain accompanying cancer treatment, pain related to the cancer, and pain due to a disease unrelated to the cancer patient.

[23] The pharmaceutical composition according to any one of [1] to [6] above, the agent according to any one of [7] to [9] above, the method according to any one of

[10] to

[12] , the use according to any one of

[13] to

[18] , or the compound for use according to any one of

[19] to

[21] , or a pharmaceutically acceptable salt thereof, wherein the cancer pain is at least pain directly caused by the cancer itself.

[24] The pharmaceutical composition according to any one of [1] to [6] above, the agent according to any one of [7] to [9] above, the method according to any one of

[10] to

[12] , the use according to any one of

[13] to

[18] , or the compound for use according to any one of

[19] to

[21] , or a pharmaceutically acceptable salt thereof, wherein the cancer pain is at least pain directly caused by the cancer itself and further includes one or more selected from pain accompanying cancer treatment, pain related to cancer, and pain due to a disease unrelated to cancer that has occurred in a cancer patient.

[0013] The present invention can provide a prophylactic or therapeutic drug for cancer pain. Furthermore, the present invention can provide a prophylactic or therapeutic drug for cancer pain that preferably does not have the side effects seen with pregabalin administration (e.g., sedative effect, etc.) and / or the side effects seen with opioid administration (e.g., dependence (psychological dependence, physical dependence), tolerance (analgesic tolerance), somnolence, etc.). Furthermore, the present invention preferably exhibits a prophylactic or therapeutic effect for cancer pain comparable to that of morphine upon single administration. Furthermore, the present invention preferably exhibits a prophylactic or therapeutic effect for cancer pain comparable to that of morphine upon oral administration.

[0014] Figure 1 shows the results of measuring pain thresholds in cancer pain model rats. Values ​​represent mean ± standard error (SE) (8 animals per group). ** indicates a significant difference between the control and compound A-treated groups at a risk level of 1% when tested by the Dunnett method. Figure 2 shows the results of evaluating the effects of compound A on the central nervous system (side effects) based on changes in spontaneous motor activity in mice following administration of compound A. Values ​​represent mean ± standard error (SE) (8 animals per group). When tested using the Dunnett method with a risk level of 5%, there was no statistically significant difference between the control and compound A-treated groups. Figure 3 shows the results of evaluating the effects of compound A on the central nervous system (side effects) based on changes in coordinated motor ability in rats following administration of compound A. Values ​​represent mean ± standard error (SE) (6 animals per group). When tested using the Dunnett or Steele method with a risk level of 5%, there was no statistically significant difference between the control and compound A-treated groups.

[0015] The present invention will be described in detail below.

[0016] The compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof will be described in detail below.

[0017] wherein m is an integer of 1 to 4; 1are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1 to 3 halogen atoms, a methoxy group optionally substituted with 1 to 3 halogen atoms, and a methylthio group optionally substituted with 1 to 3 halogen atoms.

[0018] The term "halogen atom" refers independently to any one of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.

[0019] The term "optionally substituted" means that it may be unsubstituted or may be substituted and have one or more substituents. Examples of the substituted group include R 1 represents a methoxy group substituted with at least one (preferably 1 to 3) halogen atom (e.g., fluorine atom, chlorine atom, bromine atom, or iodine atom) at substitutable positions.

[0020] Each symbol in the compound represented by formula (I) will be explained below.

[0021] m is an integer of 1 to 4, preferably an integer of 1 to 3, more preferably an integer of 1 or 2, and even more preferably 1.

[0022] R 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group optionally substituted with 1 to 3 halogen atoms, a methoxy group optionally substituted with 1 to 3 halogen atoms, and a methylthio group optionally substituted with 1 to 3 halogen atoms.

[0023] R 1 The halogen atom in is preferably a fluorine atom or a chlorine atom, and particularly preferably a chlorine atom.

[0024] R 1 As the methyl group optionally substituted with 1 to 3 halogen atoms in the formula (I), a methyl group optionally substituted with 1 to 3 fluorine atoms is preferred, and a methyl group or a trifluoromethyl group is particularly preferred.

[0025] R 1As the methoxy group which may be substituted with 1 to 3 halogen atoms in the formula (I), a methoxy group which may be substituted with 1 to 3 fluorine atoms is preferred, and a methoxy group or a trifluoromethoxy group is particularly preferred.

[0026] R 1 As the methylthio group optionally substituted with 1 to 3 halogen atoms in the formula (I), a methylthio group optionally substituted with 1 to 3 fluorine atoms is preferred, and a methylthio group or a trifluoromethylthio group is particularly preferred.

[0027] In one embodiment, R 1 are each independently a halogen atom, and preferably, each R 1 is a chlorine atom.

[0028] In another embodiment, m is 1. In another embodiment, R 1 is a halogen atom and m is 1.

[0029] In another embodiment, the compound of formula (I) or a pharmaceutically acceptable salt thereof has the following formula (I'): [In the formula, R 1 has the same meaning as defined above] or a pharmaceutically acceptable salt thereof.

[0030] In a preferred embodiment, the compound of formula (I) has the following formula: (i.e., Compound A (compound name: 1-(6-chloropyridin-2-yl)piperidin-4-amine)).

[0031] The compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof can act as a serotonin 3 receptor agonist.

[0032] Pharmaceutically acceptable salts include acid addition salts, metal salts, base addition salts, amino acid addition salts, etc. Specific examples include acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, formate, acetate, propionate, fumarate, oxalate, malonate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, maleate, dimaleate, lactate, malate, tartrate, citrate, trifluoroacetate, etc.; metal salts such as lithium salt, potassium salt, calcium salt, magnesium salt, sodium salt, zinc salt, aluminum salt, etc.; base addition salts such as ammonium salt, diethanolamine salt, ethylenediamine salt, triethanolamine salt, triethylamine salt, etc.; and amino acid addition salts such as glycine, lysine, arginine, ornithine, glutamic acid, aspartic acid, etc.

[0033] The compound of the present invention represented by formula (I) or a pharmaceutically acceptable salt thereof includes any of its internal salts, adducts, solvates or hydrates thereof, cocrystals, and the like.

[0034] One or more of the compounds represented by formula (I) or pharmaceutically acceptable salts thereof in the present invention may be administered to a patient as they are, but if necessary, the compounds represented by formula (I) or pharmaceutically acceptable salts thereof may be mixed with a pharmaceutically acceptable carrier and provided as a formulation in a form well known to those skilled in the art.

[0035] Such carriers are not particularly limited, but include commonly used pharmaceutical carriers such as excipients, lubricants, binders, disintegrants, preservatives, pH adjusters, diluents, and absorption enhancers. Specific examples of excipients include sugar derivatives such as mannitol and sorbitol, starch derivatives such as corn starch and potato starch, and cellulose derivatives such as crystalline cellulose. Lubricants include metal stearates such as magnesium stearate, and talc. Binders include hydroxypropyl cellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone. Disintegrants include cellulose derivatives such as carboxymethylcellulose and calcium carboxymethylcellulose. Preservatives include parahydroxybenzoates such as methylparaben and propylparaben, and alcohols such as chlorobutanol and benzyl alcohol. pH adjusters include inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, organic acids such as acetic acid, succinic acid, fumaric acid, and malic acid, and salts thereof. The diluent may be, for example, water for injection, etc. These pharmaceutically acceptable carriers may be used alone or in combination of two or more.

[0036] The term "cancer pain" as used herein has the meaning commonly used in the art and is not particularly limited, but may include all pain experienced by cancer patients, including at least one pain directly caused by cancer itself (such as tumor invasion, growth, or metastasis), pain associated with cancer treatment (such as postoperative pain or chronic postoperative pain, or pain associated with chemotherapy-induced neuropathy), cancer-related pain (such as low back pain associated with prolonged bed rest, lymphedema, or pressure ulcers), and pain caused by non-cancer-related diseases occurring in cancer patients (such as spondylosis osteoarthritis or migraine). Cancer pain may be either persistent pain or breakthrough pain. Furthermore, cancer pain may be either opioid-responsive or opioid-unresponsive pain. In one preferred embodiment of the present invention, cancer pain includes at least pain directly caused by cancer itself. In a further preferred embodiment of the present invention, the cancer pain includes at least pain directly caused by the cancer itself, and further includes at least one pain selected from pain occurring in association with cancer treatment (postoperative pain, postoperative chronic pain, pain associated with neuropathy due to chemotherapy, etc.), cancer-related pain (lower back pain associated with prolonged bed rest, lymphedema, bedsores, etc.), and pain caused by a non-cancer-related disease occurring concomitantly in cancer patients (spondylosis deformans, migraine, etc.).

[0037] In the present invention, "prevention" of pain includes preventing the onset of pain and delaying the onset of pain in a subject who is at risk of developing pain.

[0038] In the present invention, "treatment" of pain means alleviating, mitigating, improving, or partially or completely eliminating pain, or inhibiting the progression of severity in a subject suffering from pain. An effective amount refers to the dose of a compound or a pharmaceutically acceptable salt thereof sufficient to achieve the purpose of such prevention or treatment. For an explanation of an effective amount, see, for example, the explanation of the dosage and frequency of administration below.

[0039] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein m and R 1For the definition of m and R, please refer to the above explanation. In a preferred embodiment, the pharmaceutical composition of the present invention comprises a compound represented by formula (I') or a pharmaceutically acceptable salt thereof. Here, m and R in formula (I') 1 For the definition of , please refer to the explanation above. In a further preferred embodiment, the pharmaceutical composition of the present invention comprises Compound A.

[0040] When the compound of the present invention represented by formula (I) has an asymmetric carbon atom in the molecule, it can exist as a plurality of stereoisomers (i.e., diastereoisomers, optical isomers) based on the asymmetric carbon atom, and the active ingredient of the present invention includes any one of these stereoisomers and mixtures thereof.

[0041] The compound of the present invention represented by formula (I) or a pharmaceutically acceptable salt thereof may contain an isotope (e.g., 2 H. 3 H. 13 C. 14 C. 15 N. 18 F. 32 P. 35 S. 125 I, etc.), and deuterium conversions.

[0042] The compound of formula (I) or a pharmaceutically acceptable salt thereof in the present invention can be mixed with the above-mentioned carriers as needed and then administered orally or parenterally.Specific examples of the compound of formula (I) or a pharmaceutically acceptable salt thereof include oral or parenteral preparations such as tablets (e.g., sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (e.g., soft capsules, microcapsules, etc.), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., immediate-release preparations, sustained-release preparations, sustained-release microcapsules, etc.), aerosols, films (e.g., orally disintegrating films, oral mucosal patch films, etc.), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), drip infusions, transdermal preparations, ointments, lotions, patches, suppositories (e.g., rectal suppositories, vaginal suppositories, etc.), pellets, nasal preparations, pulmonary preparations (e.g., inhalants, etc.), and eye drops. From the viewpoint of reducing the burden on the subject animal, administration routes other than intrathecal administration are preferred. Formula (I) or a pharmaceutically acceptable salt thereof in the present invention is excellent in that it exhibits a preventive or therapeutic effect on cancer pain with a single oral administration.

[0043] The compound of the present invention represented by formula (I) or a pharmaceutically acceptable salt thereof can be formulated into the above-mentioned dosage form and then administered to, for example, humans or non-human animals (e.g., rats, mice, rabbits, sheep, pigs, cattle, cats, dogs, monkeys, etc.), preferably humans or non-human mammals, more preferably humans, and especially human patients.

[0044] The dosage and frequency of administration of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the present invention can be varied as appropriate depending on conditions such as the severity of cancer pain, the patient's age, body weight, and sex, the type of drug, dosage form, and route of administration. When administered to mice or rats, the active ingredient can be administered parenterally, for example, subcutaneously, intravenously, intraperitoneally, intramuscularly, or rectally, at a dose of about 0.1 to 10 mg / kg body weight, preferably about 0.3 to 10 mg / kg body weight, more preferably about 1 to 5 mg / kg body weight, and particularly preferably about 1 to 3 mg / kg body weight per day as the compound represented by formula (I). Furthermore, when administered orally, the active ingredient can be administered at a dose of about 1 to 100 mg / kg body weight, preferably about 3 to 100 mg / kg body weight, more preferably about 10 to 50 mg / kg body weight, and particularly preferably about 10 to 30 mg / kg body weight per day as the compound represented by formula (I). When administered to humans, the active ingredient can be administered parenterally, for example, subcutaneously, intravenously, intraperitoneally, intramuscularly, or intrarectally, per adult, at a dose of about 0.001 to 1 mg / kg body weight, preferably about 0.005 to 0.3 mg / kg body weight, and particularly preferably about 0.01 to 0.1 mg / kg body weight per dose. Furthermore, when administered orally, the active ingredient can be administered at a dose of about 0.01 to 10 mg / kg body weight, preferably about 0.05 to 3 mg / kg body weight, and particularly preferably about 0.1 to 1 mg / kg body weight per dose. The active ingredient can be administered once or in multiple divided doses per day, for example, 1 to 3 times, 1 to 2 times, or once per day.

[0045] In the present invention, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is preferably administered alone, for example, compound A. However, if necessary, two or more compounds represented by formula (I) may be administered in combination, and may also be administered in combination with other drugs, for example, other pain medications. Examples of such other pain medications include opioids, nonsteroidal anti-inflammatory drugs, pregabalin, fluvoxamine, and pharmaceutically acceptable salts thereof. Examples of opioids include strong opioids and weak opioids. Specific examples include codeine, morphine, oxycodone, fentanyl, remifentanil, meperidine, buprenorphine, pentazocine, pethidine, butorphanol, tramadol, naloxone, etc. Examples of non-steroidal anti-inflammatory drugs include aspirin, ethenzamide, diflunisal, loxonin, ibuprofen, diclofenac, ketoprofen, naproxen, piroxicam, and indomethacin.

[0046] When two or more compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention are used in combination and / or when they are used in combination with other drugs, the drugs may be administered simultaneously, sequentially, or separately. In addition, the drugs may be formulated as a combination containing two or more drugs, or each drug may be formulated as a separate composition.

[0047] The compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the present invention may be commercially available or may be produced according to a known or per se known method. For example, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof can be produced by the method described in Patent Document 1 or 2. Compound A may also be commercially available.

[0048] Whether the compound of the present invention can be used for the prevention or treatment of cancer pain can be evaluated, for example, by using a cancer pain model animal in a conventionally known test system appropriately selected from known methods, comparing a group administered with a compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof with a group not administered with the compound, measuring the pain threshold (e.g., 1, 3, 6, and 24 hours after administration). Based on known statistical processing methods, it is preferable that there is a significant tendency or a significant difference between the two groups, and more preferably there is a significant difference. The compound of formula (I) of the present invention or a pharmaceutically acceptable salt thereof can also be used as a threshold-elevating agent for cancer pain (e.g., 1, 3, and 6 hours after administration).

[0049] Pharmaceutical compositions or agents containing the compound of formula (I) or a pharmaceutically acceptable salt thereof can be formulated by appropriately blending the compound of formula (I) or a pharmaceutically acceptable salt thereof, which is the active ingredient, with pharmaceutically acceptable carriers and additives, as needed, according to known methods for manufacturing pharmaceutical preparations (e.g., methods described in the Japanese Pharmacopoeia, etc.). The blending ratio of additives may be appropriately set based on the ranges commonly used in the pharmaceutical field. The additives that can be blended are not particularly limited, and examples include various additives such as colorants, flavorings, and fragrances.

[0050] In this disclosure, the term "about" is used to encompass small deviations, for example. These terms may refer to, for example, within ±10%, ±5%, ±2%, ±1%, ±0.5%, ±0.2%, ±0.1%, or ±0.05%. Such ranges also include within the experimental error inherent in standard methods used to measure and / or quantify a given value or range.

[0051] The present invention includes various combinations of the above-described configurations within the technical scope of the present invention, as long as the effects of the present invention are achieved.

[0052] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to these examples, and the explanation will be made on the basis that many modifications and manufacturing techniques of the basic technology of the present invention can be implemented by those skilled in the art.

[0053] Experiment 1: Pain treatment effects of Compound A and existing drugs (Experimental method) MRMT-1 (rat breast cancer cells) 3 x 10 cells were injected into the medullary cavity of the proximal tibia metaphysis of the right limb of 5-week-old female Crl:CD (SD) SPF rats (Charles River Japan). 4 Cells / 20 μL / body were injected to prepare a bone metastasis model (day 0). On day 10 after cancer cell transplantation, the animals were divided into four groups of eight animals each (control (distilled water (trade name: Otsuka Distilled Water) (Otsuka Pharmaceutical Factory, Inc.) administered group), 10 mg / kg Compound A administered group, 30 mg / kg Compound A administered group, and morphine administered group) as shown in Table 1 below. On day 11 after cancer cell transplantation, each drug was administered orally or subcutaneously at a volume of 2 mL / kg. The pain threshold (g) of the right footpad was measured blinded using a Dynamic Plantar Aesthesiometer (37450, manufactured by Ugo Basile) at 1, 3, 6, and 24 hours after administration, and the mean value of the area under the pain threshold-time curve (AUC (g hr)) up to 24 hours after administration was calculated for each group.

[0054]

[0055] (Results of Experiment 1) The results are shown in Figure 1. Compared to the control group, the group administered 10 mg / kg of Compound A and the group administered 30 mg / kg of Compound A significantly increased the cancer pain threshold and exhibited analgesic effects. The area under the pain threshold-time curve AUC (g hr) up to 24 hours after administration of these two groups was not statistically significantly different from the group administered subcutaneously with morphine.

[0056] Experiment 2: Evaluation of the effects (side effects) of Compound A on the central nervous system based on changes in spontaneous motor activity and coordination caused by Compound A (Experimental method) (1) Measurement of spontaneous motor activity Five- to six-week-old male ICR / SPF mice (Japan SLC Co., Ltd.) were divided into five groups of eight mice each, as shown in Table 2 below: a control group (administered distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.)), two groups administered with 10 mg / kg Compound A, and two groups administered with 30 mg / kg Compound A. Compound A or distilled water was orally administered to the mice at a volume of 10 mL / kg, and one or three hours after administration of Compound A or distilled water, the mice were moved to measurement cages, and spontaneous motor activity was measured for 30 minutes using Supermex (registered trademark) (manufactured by Muromachi Kikai Co., Ltd.). The results are shown in Figure 2.

[0057]

[0058] (2) Measurement of Coordination Ability Male SD / SPF rats (Japan SLC Co., Ltd.) aged 5 to 6 weeks were used in the experiment. The experimental schedule consisted of training using a rotarod (SN445, Shinano Seisakusho Co., Ltd.) for three days (six times per day) starting three days before the administration date. On the administration date, pre-values ​​(the time spent on the rotarod before administration of Compound A or distilled water) were measured twice, and rats with a time spent on the rotarod of 180 seconds or more were selected. As shown in Table 3 below, the rats were divided into three groups of six rats each: a control group (administered distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.)), a 10 mg / kg Compound A group, and a 30 mg / kg Compound A group. Compound A or distilled water was orally administered at a volume of 10 mL / kg, and the rotarod residence time was measured 1, 3, 6, and 24 hours after administration under test conditions of a rotation speed of 10 rpm and a cutoff time of 180 seconds. The results are shown in Figure 3.

[0059]

[0060] (Results of Experiment 2) From the results of Figure 2, there was no significant change in activity level in any of the compound A administration groups compared to the control group. Therefore, it was shown that there was no significant change in spontaneous motor activity in any of the compound A administration groups compared to the control group. Furthermore, from the results of Figure 3, there was no significant change in coordinated motor ability in any of the compound A administration groups compared to the control group. The results of Experiment 2 showed that administration of 10 to 30 mg / kg of compound A to mice and rats did not suppress spontaneous motor activity or coordinated motor ability.

[0061] (Summary of Results) The results of Experiments 1 and 2 above show that Compound A does not suppress locomotor activity or coordination at doses that have an analgesic effect. This suggests that Compound A is useful as an active ingredient in an analgesic that can be taken without affecting the central nervous system (side effects such as sedation).

[0062] The composition of the present invention is useful as a pharmaceutical composition for the prevention or treatment of cancer pain.

Claims

1. A pharmaceutical composition for preventing or treating cancer pain, comprising a compound represented by the following formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

2. R 1 The pharmaceutical composition of claim 1 , wherein each is independently a halogen atom.

3. Each R 1 The pharmaceutical composition according to claim 1 or 2, wherein is a chlorine atom.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein m is 1.

5. A compound represented by formula (I) or a pharma- ceutically acceptable salt thereof, wherein the compound represented by formula (I') is [In the formula, R 1 The pharmaceutical composition according to any one of claims 1 to 4, which is a compound represented by the formula: Figure US081202333-20120323-C00002 or a pharma- ceutically acceptable salt thereof.

6. A compound represented by formula (I) or a pharma- ceutically acceptable salt thereof, wherein the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof is represented by the following formula: The pharmaceutical composition according to any one of claims 1 to 5, which is a compound represented by the formula: or a pharma- ceutically acceptable salt thereof.

7. A preventive or therapeutic agent for cancer pain, comprising a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

8. A cancer pain threshold elevating agent comprising a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

9. A method for preventing or treating cancer pain, which comprises administering to a human or a non-human animal an effective amount of a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

10. A method for increasing the threshold of cancer pain, which comprises administering to a human or non-human animal an effective amount of a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

11. Use of a compound represented by formula (I) or a pharma- ceutical acceptable salt thereof for the manufacture of a pharmaceutical composition for the prophylaxis or treatment of cancer pain, or an agent for the prophylaxis or treatment of cancer pain. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

12. Use of a compound represented by formula (I) or a pharma- ceutical acceptable salt thereof for the manufacture of a pharmaceutical composition for increasing the cancer pain threshold or an agent for increasing the cancer pain threshold. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

13. Use of a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof for the prevention or treatment of cancer pain. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

14. Use of a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof for increasing the threshold of cancer pain. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

15. A compound of formula (I) or a pharma- ceutically acceptable salt thereof for use in the prevention or treatment of cancer pain. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

16. A compound represented by formula (I) or a pharma- ceutically acceptable salt thereof for use in increasing cancer pain threshold. [In the formula, m is an integer from 1 to 4; 1 are each independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.

17. The pharmaceutical composition according to any one of claims 1 to 6, the agent according to claim 7 or 8, the method according to claim 9 or 10, the use according to any one of claims 11 to 14, or the compound or a pharma- ceutical acceptable salt thereof for use according to claim 15 or 16, wherein the cancer pain is at least one selected from pain directly caused by the cancer itself, pain accompanying cancer treatment, pain related to cancer, and pain due to a disease unrelated to cancer occurring concomitantly in a cancer patient.

Citation Information

Patent Citations

  • Aminopiperidine* its manufacture* intermediate and medicine

    JP1981036481A

  • Use of 4-amino-1-(2-pyridyl)Piperidine derivative

    JP1995145166A

  • Treatment of pain with serotonin 3 receptor agonists

    JP7090344B2

  • Treatment of pain with serotonin-3 receptor agonist

    WO2019004292A1